Globus Medical Past Earnings Performance
Past criteria checks 0/6
Globus Medical's earnings have been declining at an average annual rate of -3.1%, while the Medical Equipment industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 23.1% per year. Globus Medical's return on equity is 2.2%, and it has net margins of 3.7%.
Key information
-3.1%
Earnings growth rate
-5.6%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 23.1% |
Return on equity | 2.2% |
Net Margin | 3.7% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Globus Medical Stock: Re-Rated After A Solid Year
Nov 18Globus Medical (NYSE:GMED) Has A Rock Solid Balance Sheet
Nov 04Globus Medical, Inc.'s (NYSE:GMED) Shareholders Might Be Looking For Exit
Oct 14Globus Medical: A Post Acquisition Analysis
Aug 26Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors
Jun 28An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued
Apr 08Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly
Mar 20Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock
Feb 27Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?
Feb 09Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings
Jan 17Globus Medical: Merger Overhang Lingering
Nov 27Globus Medical: Almost Having My Back
Sep 13Globus Medical: Slightly Too Pricey Right Now
Aug 07Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy
Jul 18Globus Medical Q4 2022 Earnings Preview
Feb 20Globus Medical: An Impressive Long-Term Revenue Growth Play
Jan 08Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line
Nov 08Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact
Sep 02Revenue & Expenses Breakdown
How Globus Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 2,479 | 92 | 969 | 181 |
30 Jun 24 | 2,237 | 41 | 885 | 175 |
31 Mar 24 | 1,898 | 67 | 770 | 160 |
31 Dec 23 | 1,568 | 123 | 643 | 124 |
30 Sep 23 | 1,226 | 158 | 517 | 91 |
30 Jun 23 | 1,097 | 204 | 467 | 81 |
31 Mar 23 | 1,069 | 201 | 454 | 77 |
31 Dec 22 | 1,023 | 190 | 432 | 73 |
30 Sep 22 | 998 | 155 | 421 | 105 |
30 Jun 22 | 974 | 155 | 410 | 102 |
31 Mar 22 | 961 | 142 | 411 | 100 |
31 Dec 21 | 958 | 149 | 408 | 97 |
30 Sep 21 | 942 | 187 | 394 | 62 |
30 Jun 21 | 928 | 184 | 386 | 60 |
31 Mar 21 | 826 | 122 | 359 | 84 |
31 Dec 20 | 789 | 102 | 355 | 85 |
30 Sep 20 | 767 | 95 | 355 | 85 |
30 Jun 20 | 747 | 89 | 354 | 85 |
31 Mar 20 | 793 | 148 | 363 | 61 |
31 Dec 19 | 785 | 155 | 355 | 60 |
30 Sep 19 | 770 | 146 | 346 | 58 |
30 Jun 19 | 743 | 143 | 333 | 59 |
31 Mar 19 | 722 | 150 | 322 | 57 |
31 Dec 18 | 713 | 156 | 312 | 55 |
30 Sep 18 | 693 | 144 | 300 | 53 |
30 Jun 18 | 676 | 134 | 289 | 49 |
31 Mar 18 | 655 | 118 | 276 | 46 |
31 Dec 17 | 636 | 107 | 267 | 44 |
30 Sep 17 | 612 | 107 | 256 | 42 |
30 Jun 17 | 595 | 108 | 247 | 41 |
31 Mar 17 | 581 | 105 | 235 | 41 |
31 Dec 16 | 564 | 104 | 222 | 41 |
30 Sep 16 | 553 | 118 | 214 | 41 |
30 Jun 16 | 554 | 118 | 212 | 40 |
31 Mar 16 | 548 | 116 | 212 | 38 |
31 Dec 15 | 537 | 113 | 210 | 36 |
30 Sep 15 | 518 | 103 | 205 | 35 |
30 Jun 15 | 499 | 99 | 200 | 34 |
31 Mar 15 | 481 | 96 | 193 | 33 |
31 Dec 14 | 467 | 92 | 189 | 31 |
30 Sep 14 | 454 | 86 | 186 | 30 |
30 Jun 14 | 443 | 83 | 184 | 28 |
31 Mar 14 | 436 | 70 | 184 | 27 |
Quality Earnings: GMED has a large one-off loss of $279.1M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: GMED's current net profit margins (3.7%) are lower than last year (12.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GMED's earnings have declined by 3.1% per year over the past 5 years.
Accelerating Growth: GMED's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GMED had negative earnings growth (-42%) over the past year, making it difficult to compare to the Medical Equipment industry average (15%).
Return on Equity
High ROE: GMED's Return on Equity (2.2%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/02 19:55 |
End of Day Share Price | 2024/12/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Globus Medical, Inc. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jason Wittes | Aegis Capital Corporation |
Ishan Majumdar | Baptista Research |
Matt Miksic | Barclays |